Le Lézard
Classified in: Health
Subjects: NEW PRODUCTS/SERVICES, HEALTH, Clinical Study

Curium Confirms No Supply Challenges in North America and Europe for its Eclipse Phase 3 Clinical Trial


PARIS, March 14, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, confirmed today that the company has no foreseeable supply challenges of 177Lu-PSMA-I&T for the company's ECLIPSE Phase 3 clinical trial (NCT05204927) ongoing in the USA, France, Spain, and Italy. Since patient enrollment started in March 2022, the ECLIPSE Phase 3 trial has experienced reliable and uninterrupted supply of 177Lu-PSMA-I&T.

ECLIPSE is a Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer.

Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented: "We continue to make strong progress in conducting our ECLIPSE Phase 3 clinical trial in North America and in Europe. Reliability of clinical trial supply is extremely important for our patients and investigators, and we are pleased to confirm that our clinical trial supply with 177Lu-PSMA-I&T remains uninterrupted. Curium is committed to the ECLIPSE clinical trial as well as our other ongoing clinical trials in oncology to further our mission of redefining the experience of cancer through our trusted legacy in nuclear medicine." For more information about the ECLIPSE trial: www.eclipseclinicaltrial.org To locate a clinical trial site or contact Curium's clinical trial: [email protected]

About Curium

Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ?Curium' honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com

For more information:
Ross Bethell
VP, Head of Global Communications
[email protected]



These press releases may also interest you

at 04:15
Brenus Pharma Wins French Tech Saint-Etienne Lyon's BIG Start-up of the Year Award
During its annual event "BIG UP", French Tech Saint-Etienne Lyon awarded the BIG Start-up of the Year trophy, honoring a start-up that exemplifies the region's innovation and richness. French Tech Saint-Etienne Lyon, a non-profit association...

at 03:05
Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research
Owkin, the first end-to-end AI-biotech unicorn that provides best-in-class AI-driven precision drug discovery, development and diagnostics, has announced its expansion into the DACH region (Germany, Austria and Switzerland) following partnerships...

at 03:05
Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323
We are excited to share our latest development status. We are pleased to announce that the enrollment of patients in the Phase III clinical trial of DFP-14323 in combination with Afatinib (20 mg/day) versus Afatinib (40 mg/day) alone in stage...

at 02:50
Two Belgian hospitals live with Sectra's public cloud service for medical imaging based on Microsoft Azure
Two hospitals in Belgium are successfully live with the public cloud service from international medical imaging IT and cybersecurity company Sectra (STOCKHOLM: SECT-B). As the first to use Sectra One Cloud in the Benelux countries, the two hospitals...

at 02:03
Barrington James Announces Strategic Acquisition of S3 Science Recruitment
Barrington James, a global leader in Life Science Recruitment, proudly announces the acquisition of S3 Science Recruitment, a firm renowned for its expertise in drug discovery, medical research, and the broader field of life sciences. Terms of the...

at 02:00
Philips appoints Ling Liu as Chief Region Leader of Philips Greater China
July 3, 2024 Amsterdam, the Netherlands ? Royal Philips , a global leader in health technology, today announced the appointment of Ms Ling Liu as the Chief Region Leader of Philips Greater China, effective immediately. Ms Liu is now a member of...

More news about Health...


News published on and distributed by: